Business
NetScientific Invests in Breakout Labs Companies
NetScientific Invests in Breakout Labs Companies.
About this update from Emv Capital Plc
[{"type":"text","content":"\n \nRNS Number : 0808N NetScientific PLC 23 July 2014 \n \n\n \n23 July 2014\n \nNetScientific invests in a further two Breakout Labs portfolio companies\n \n \nNetScientific plc (AIM:NSCI, 'NetScientific' or 'The Group'), the biomedical and healthcare technology investment group, is pleased to announce it has made a further two investments in portfolio companies from Breakout Labs, Peter Thiel's revolving philanthropic fund that supports early-stage companies working on technological breakthroughs.\n \nG-Tech Medical is developing a wireless, wearable, disposable patch, which will help diagnose the root causes of Functional Gastrointestinal Disorders ('FGIDs'). FGIDs afflict more than 60 million people annually in the US, and are a large burden to the health care system. The G-Tech patch will measure and characterize the activity of the main digestive organs under normal daily conditions to help pinpoint the source of the dysfunction. It will allow physicians to quickly determine that a functional problem exists, in many cases allowing them to skip the current invasive, expensive anatomic testing sequence. By identifying the specific source and nature of the dysfunction it will enable them to more effectively target their therapies, bringing relief to patients faster and at lower cost. \n \nLongevity Biotech is developing an entirely new approach to therapeutics development via artificial protein technology (\"Hybridtides\"). Hybridtides® are peptide molecules that contain both α- and β-amino acid subunits, which makes them resistant to breakdown by natural digestive enzymes, tunable to very stable conformations, and able to mimic information-rich surfaces displayed by natural proteins or peptides, enabling new drug designs which are more stable and more clinically active. Current work will establish the platform's potential in a clinically important indication in cardiovascular disease, pulmonary arterial hypertension. \n \nThe new investments represent the first outside financing for both G-Tech and Longevity Biotech.\n \n \nFarad Azima, CEO of NetScientific commented:\n \n\"We are delighted to continue working with Breakout Labs in their quest to identify and foster revolutionary life science companies at the forefront of scientific in...